Pharmaceutical company PharmaDrug Inc. LMLLF — which focuses on cannabis, psychedelics and naturally-derived medicines — has launched a sponsored research agreement with the University of Michigan to study the psychedelic DMT.
The research will be led by Dr. Jimo Borjigin, in an effort to develop novel therapeutic strategies for DMT using animal models.
“I have a long history in studying DMT," said Dr. Jimo Borjigin. "I have dedicated my research in understanding how the brain functions and its effects on the heart in normal and abnormal states that can translate to relevant clinical uses.”
A Pharma Focus on DMT: The company stated that it’s strategy around the pharmaceutical development of psychedelic therapies will revolve around the DMT molecule.
“Our research collaboration with the University of Michigan and its commitment on consciousness science is essential to our psychedelic pharmaceutical strategy of creating a unique portfolio of DMT therapies targeting rare disorders while also focusing on foundational research with DMT to explore and evaluate its therapeutic potential across all physiological areas of the human body,” said CEO Daniel Cohen.
Photo by Hans Reniers on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
